Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Share News (VRP)

  • There is currently no data for VRP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DIRECTOR DEALINGS SUMMARY: Glencore Non-Executive Cuts Stake

Fri, 22nd May 2015 13:01

Director Dealings Summary - Week Ended May 22        
Company Name Position Number of Shares Resulting Holding *Note GBP Value
             
BUYS            
             
Topps Tiles Matthew Williams CEO 1 million 1.7 million   1,270,000
Countrywide Alison Platt CEO 41,700 41,700 Appointed CEO in September 2014. 248,000
Rank Group Henry Birch CEO 100,000 100,000 Same day as  Rank said it expects  full year results to meet management expectations.  205,000
Homeserve John Gibson Chairman 40,000 115,000 Day after reporting higher profit and said it would pay a special dividend of GBP97 million. 172,000
Sage Group Jonathan Howell Non-Executive Director 18,167 Undisclosed   103,000
AG Barr Stuart Lorimer CFO 14,000 1.1 million   87,000
Homeserve Ben Mingay Non-Executive Director 20,000 40,000 Day after reporting higher profit and said it would pay a special dividend of GBP97 million. 86,000
Inspired Capital Jeremy Coombes Interim CEO 535,000 2.9 million   75,000
Rank Group Clive Jennings CFO 25,000 25,000 Same day as  Rank said it expects  full year results to meet management expectations..  51,000
STM Group Michael Riddell Chairman 137,000 Undisclosed Week after STM said it made good start to 2015 and said trading so far this year is in line with its expectations. 49,000
Homeserve Stella David Non-Executive Director 10,450 28,138 2 days after reporting higher profit and said it would pay a special dividend of GBP97 million. 45,000
Mitchells & Butlers Eddie Irwin Non-Executive Director 10,000 30,000   45,000
Amara Mining John McGloin Chairman 271,249 1.6 million   41,000
McBride Chris Smith CFO 25,657 25,657 Appointed in January. 24,000
Oxford Biomedica Tim Watts CFO 194,174 5.8 million   19,000
Symphony Environmental Michael Stephen Deputy Chairman 151,000 933,998   15,000
Symphony Environmental Michael Laurier CEO 150,000 23 million   14,000
Verona Pharma David Ebsworth Chairman 300,000 3.6 million Week after Verona Pharma  posted a widened pretax loss for 2014. 11,000
Lekoil Greg Eckersley Non-Executive Director 50,000 2.8 million Week after Lekoil said its pretax loss narrowed as administrative and finance costs fell. 10,000
Oxford Biomedica Andrew Heath Non-Executive Director 100,000 1.1 million   10,000
Mortgage Advice Bureau Lucy Tilley CFO 4,500 4,500 Appointed in March. Was previously a director in Canaccord Genuity's corporate broking team, which worked on company's AIM listing. 9,900
Airea Roger Salt CFO 58,738 228,738   9,000
Symphony Environmental Ian Bristow CFO 100,000 1.2 million   9,000
K3 Business Technology Brian Davies CFO 2,253 9,537 Bought shares from CEO David Bolton 5,600
Verona Pharma Biresh Roy CFO 150,000 900,000 Week after Verona Pharma  posted a widened pretax loss for 2014. 5,000
Symphony Environmental Nirj Deva Chairman 50,000 363,925   4800
Verona Pharma Jan-Anders Karlsson CEO 135,000 2.9 million Week after Verona Pharma  posted a widened pretax loss for 2014. 4,700
Symphony Environmental Nicholas Clavel Non-Executive Director 50,000 550,000   4,500
             
SELLS            
             
Glencore William Macaulay Non-Executive Director 28 million 42 million Sold by FR Galaxy Holdings, an investment vehicle connected to Macaulay. 84,000,000
Moneysupermarket Simon Nixon Founder & non-executive deputy chairman 20 million 69.8 million The amount of shares sold is at the top end of the range. Credit Suisse, the sole bookrunner on the placing, said it would sell a stake of between 2.8% and 3.7% on behalf of Nixon, who retains a 12.8% holding. 56,000,000
Merlin Entertainments Nick Mackenzie Manager 440,000 1.5 million Same day as Merlin reported growth in revenue boosted by new site openings, features and good weather, as it continues strategic expansion plans. 2,000,000
Countrywide Grenville Turner Chairman 300,000 171,524   1,800,000
Hays Paul Venables CFO 750,000 953,014   1,200,000
Sthree Justin Hughes Corporate Executive Officer 267,500 390,867 Has sold parcels of shares in quick succession since May 12. 1,000,000
Euromoney Peter Ensor Chairman 20,421 175,918 Same day as interim ex-dividend date. 245,000
Bloomsbury Publishing Nigel Newton CEO 132,651 1.1 million Day after Bloomsbury posted a small rise in pretax profit and said trading in its current year has been good across all of its divisions. 232,000
ITV David Osborn HR Director 35,900 Nil   97,000
Rolls-Royce Jason Smith Divisional CEO 2,850 19,582   29,000
K3 Business Technology David Bolton CEO 2,253 994,961 Sold shares to CFO Brian Davies.  
             
*Note: A recent company event around the time of the dealing does not suggest the dealing took place because of that event.
When a spouse or related party to a director buys shares, the resulting holding is the beneficial holding of the director
             
Contact: +44 207 199 0340; newsroom@alliancenews.com; @AllNewsTeam      
             
Copyright 2015 Alliance News Limited. All Rights Reserved.        

More News
5 Nov 2015 10:50

Verona Pharma Completes Patient Enrolment For RPL554 Studies

Read more
14 Oct 2015 10:40

Verona Pharma: First Patients Dosed In RPL554 Combination Study

Read more
29 Sep 2015 09:18

Verona Pharma rallies on positive drug study results

(ShareCast News) - Shares in Verona Pharma rallied after it announced positive headline data from the third and final part of a clinical study on its RPL554 drug for the treatment of chronic obstructive pulmonary disease. The drug development company said the primary objective of this part of the st

Read more
29 Sep 2015 07:58

Verona Pharma Shares Up 10% On Good RPL554 Study Results

Read more
8 Sep 2015 08:28

Verona Pharma plunges as interim loss widens

(ShareCast News) - Shares in Verona Pharma plunged over 12% early on Tuesday, after the pharmaceutical company posted a wider interim pre-tax loss. The London-listed company, which attributed the wider loss to an increase in research and development spending, saw its pre-tax loss for the six months

Read more
8 Sep 2015 07:23

Verona Pharma Loss Widens On Higher Research And Development Spending

Read more
12 Jun 2015 11:19

LONDON MIDDAY BRIEFING: Greece Remains Optimistic For Debt Deal

Read more
12 Jun 2015 10:27

WINNERS & LOSERS: Petra Diamonds Loses Sparkle On Lower Quality Stones

Read more
12 Jun 2015 09:46

Verona Pharma to launch secondary listing in Germany

AIM-listed drug developer Verona Pharma has carried out a second listing in Germany. The move will be a way of further raising its profile within continental Europe and to increase the potential for investors in German-speaking Europe to trade in the company's shares, it said. The group will be lis

Read more
12 Jun 2015 08:40

Verona Pharma Takes Secondary Listing In Germany (ALLISS)

Read more
11 Jun 2015 07:52

Verona Pharma Begins Phase 2A Dose-Finding Trial Of RPL554 In Asthma

Read more
11 Jun 2015 07:32

LONDON MORNING BRIEFING: Royal Mail Falls, RBS Gains On UK Govt Moves

Read more
11 Jun 2015 05:26

AGM, EGM Calendar - Week Ahead

Read more
10 Jun 2015 15:00

AGM, EGM Calendar - Week Ahead

Read more
10 Jun 2015 05:30

AGM, EGM Calendar - Week Ahead

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.